National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts.org
Search Results

From the 1/7/2022 release of VAERS data:

Found 1,514 cases where Vaccine is HPV2 and Serious

Government Disclaimer on use of this data



Case Details

This is page 14 out of 152

Result pages: prev   5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23   next


VAERS ID: 387212 (history)  
Form: Version 1.0  
Age: 21.0  
Sex: Female  
Location: Foreign  
Vaccinated:2009-11-04
Onset:0000-00-00
Submitted: 2010-05-11
Entered: 2010-05-11
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / 2 UN / IM

Administered by: Other       Purchased by: Other
Symptoms: Feeling abnormal, Hepatitis viral, Infectious mononucleosis
SMQs:, Liver infections (narrow), Dementia (broad)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, 0 days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC Split Type: B0651359A

Write-up: This case was reported by a pharmacist and described the occurrence of glandular fever in a 22-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). Previous vaccination included the 1st dose of CERVARIX (GlaxoSmithKline, intramuscular) given on 7 October 2009. On 4 November 2009 the subject received the 2nd dose of CERVARIX (1 injection, intramuscular). In "mid" November 2009, less than one month after vaccination with CERVARIX, the subject experienced glandular fever and viral hepatitis ("as a result of the glandular fever"). The subject was scheduled to receive the third dose of CERVARIX on 08 April 2010; however a clinical decision was made to not administer the subject the CERVARIX vaccine as she still "did not feel 100%". At the time of reporting the events were improved. Verbatim text received: On 05/05/2010 a community pharmacist reported that a 22-year-old female patient was administered a first dose of CERVARIX vaccine (batch number: AHPVA063CA and expiry date: 04/2001) intramuscularly on 07/10/2009 and a second dose of CERVARIX vaccine intramuscularly on 04/11/2009. Subsequently, in mid November (date unspecified) the patient developed glandular fever and also developed viral hepatitis as a result of the glandular fever. Furthermore, the patient was admitted to hospital for her condition for an unknown period of time. The pharmacist reported that the patient had returned back to work in January and on 08/04/2010 the patient had come into the surgery to receive her third dose of CERVARIX vaccine. The pharmacist reported that on 08/04/2010 the patient mentioned that she still ''did not feel 100%'' and therefore a clinical decision was made to not administer the patient the CERVARIX vaccine. No further information was available at the time of reporting.


VAERS ID: 389152 (history)  
Form: Version 1.0  
Age: 17.0  
Sex: Female  
Location: Foreign  
Vaccinated:2009-12-02
Onset:2009-12-02
   Days after vaccination:0
Submitted: 2010-05-24
   Days after onset:172
Entered: 2010-05-24
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS AHPVA60BB / UNK UN / IM

Administered by: Other       Purchased by: Other
Symptoms: Body temperature increased, Headache, Hypotension, Malaise, Nausea
SMQs:, Anaphylactic reaction (broad), Acute pancreatitis (broad), Neuroleptic malignant syndrome (broad), Gastrointestinal nonspecific symptoms and therapeutic procedures (narrow), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Dehydration (broad), Hypokalaemia (broad)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, 0 days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions: Fainting
Allergies:
Diagnostic Lab Data: UNK
CDC Split Type: B0653330A

Write-up: This case was reported by a foreign regulatory authority (Agency # GB-MHRA-ADR 20625300) and described the occurrence of feeling unwell in a 17-year-old female subject who was vaccinated with CERVARIX. The subject''s medical history included fainting. On 2 December 2009 the subject received unspecified dose of CERVARIX (.5 ml, intramuscular). On 2 December 2009, on the same day after vaccination with CERVARIX, the subject experienced feeling unwell, headache, nausea, body temperature increased and hypotension. The subject was hospitalised. On 3 December 2009, the events were resolved. Reported by the patient''s mother: Complaining of feeling very unwell (severe headache and nausea). Rise in body temperature. Attended accident and emergency (A&E). Remained overnight. Hypotensive.


VAERS ID: 389153 (history)  
Form: Version 1.0  
Age: 18.0  
Sex: Female  
Location: Foreign  
Vaccinated:2008-02-09
Onset:2008-02-12
   Days after vaccination:3
Submitted: 2010-05-24
   Days after onset:831
Entered: 2010-05-24
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / UNK UN / IM

Administered by: Other       Purchased by: Other
Symptoms: Convulsion
SMQs:, Systemic lupus erythematosus (broad), Convulsions (narrow), Noninfectious encephalitis (broad), Noninfectious encephalopathy/delirium (broad), Noninfectious meningitis (broad), Generalised convulsive seizures following immunisation (narrow), Hypoglycaemia (broad)

Life Threatening? Yes
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC Split Type: B0653334A

Write-up: This case was reported by a foreign regulatory authority (# GB-MHRA-ADR 20623943) and described the occurrence of seizure in a 18-year-old female subject who was vaccinated with CERVARIX. On 9 February 2008 the subject received unspecified dose of CERVARIX (intramuscular). On 12 February 2008, 3 days after vaccination with CERVARIX, the subject experienced seizure. The regulatory authority reported that the event was life threatening. At the time of reporting the event was resolved. Verbatim Text: Generalized seizure.


VAERS ID: 389949 (history)  
Form: Version 1.0  
Age: 12.0  
Sex: Female  
Location: Foreign  
Vaccinated:2010-04-29
Onset:2010-04-29
   Days after vaccination:0
Submitted: 2010-06-03
   Days after onset:35
Entered: 2010-06-03
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS AHPVA063CA / UNK UN / IM

Administered by: Other       Purchased by: Other
Symptoms: Breath sounds abnormal, Dizziness, Dysphagia, Rash
SMQs:, Anaphylactic reaction (broad), Anticholinergic syndrome (broad), Oropharyngeal conditions (excl neoplasms, infections and allergies) (narrow), Acute central respiratory depression (narrow), Guillain-Barre syndrome (broad), Noninfectious encephalitis (broad), Noninfectious encephalopathy/delirium (broad), Noninfectious meningitis (broad), Gastrointestinal nonspecific symptoms and therapeutic procedures (broad), Vestibular disorders (broad), Hypersensitivity (narrow), Respiratory failure (narrow), Drug reaction with eosinophilia and systemic symptoms syndrome (broad)

Life Threatening? Yes
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions: Unconfirmed latex allergy.
Allergies:
Diagnostic Lab Data: Heart rate, 90; Respiratory rate, 20
CDC Split Type: B0657210A

Write-up: This case was reported by the foreign regulatory authority (# GB-MHRA-ADR 20629678) and described the occurrence of rash in a 12-year-old female subject who was vaccinated with CERVARIX. On 29 April 2010 the subject received unspecified dose of CERVARIX (0.5 ml, intramuscular). On 29 April 2010 the subject received unspecified dose of CERVARIX (0.5 ml, intramuscular). On 29 April 2010, at an unspecified time after vaccination with CERVARIX, the subject experienced rash (chest, neck and arms), dizziness, difficulty swallowing and breath sounds abnormal. The regulatory authority reported that the events were life threatening. At the time of reporting the events were improved. Verbatim text: Rash chest, neck and arms. Dizzy. Difficulty swallowing. Breathing more raspy.


VAERS ID: 390147 (history)  
Form: Version 1.0  
Age: 10.0  
Sex: Female  
Location: Foreign  
Vaccinated:2010-04-09
Onset:2010-05-03
   Days after vaccination:24
Submitted: 2010-06-07
   Days after onset:35
Entered: 2010-06-07
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS AHPV059AG / 1 UN / IM

Administered by: Other       Purchased by: Other
Symptoms: Status epilepticus
SMQs:, Systemic lupus erythematosus (broad), Convulsions (narrow), Generalised convulsive seizures following immunisation (narrow), Hypoglycaemia (broad)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, 0 days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC Split Type: B0658989A

Write-up: This case was reported by a regulatory authority (#117631) and described the occurrence of non convulsive status epilepticus in a 11-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). The subject had a family history of metabolic disease and epilepsy. On 9 April 2010, the subject received 1st dose of CERVARIX (intramuscular, unknown injection site). On 3 May 2010, 24 days after vaccination with CERVARIX, the subject experienced non convulsive status epilepticus. The subject was hospitalised. At the time of reporting the event was resolved. The regulatory authority reported that the event was possibly related to vaccination with CERVARIX. On 12 May 2010, the subject received the 2nd dose of CERVARIX. At the time of reporting, no adverse event had occurred.


VAERS ID: 390237 (history)  
Form: Version 1.0  
Age: 16.0  
Sex: Female  
Location: Foreign  
Vaccinated:2010-03-23
Onset:0000-00-00
Submitted: 2010-06-08
Entered: 2010-06-08
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS AHPVA070AA / 3 UN / IJ

Administered by: Other       Purchased by: Other
Symptoms: Feeling abnormal, Guillain-Barre syndrome, Intensive care, Pain, Paralysis
SMQs:, Peripheral neuropathy (narrow), Dementia (broad), Guillain-Barre syndrome (narrow), Noninfectious encephalitis (broad), Demyelination (narrow), Conditions associated with central nervous system haemorrhages and cerebrovascular accidents (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, 0 days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC Split Type: B0658275A

Write-up: This case was reported by a nurse via a company representative, and described the occurrence of guillian barre syndrome in a 17-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). Previous vaccination included the first and second dose of CERVARIX (GlaxoSmithKline) given on 22 September 2009 and 10 November 2009 respectively. On 23 March 2010 the subject received the 3rd dose of CERVARIX (1 injection). 10 days after vaccination with the 3rd dose of CERVARIX, the subject felt poorly. The patient was admitted into ''ICU where she stayed for six weeks and was diagnosed with Guillian Barre Syndrome'' (unspecified date of onset). The nurse also reported that the patient is ''now out of ICU but still in hospital with pain and paralysis''. At the time of reporting the outcome of the events was unspecified. On the 1st of June 2010 a nurse (lead for HPV) reported via a GSK representative that a 17 year old female patient was administered three doses of the CERVARIX vaccine. The first dose was administered on the 22nd September 2009 (batch AHPVA043BB), the second dose on the 10th November 2009 (Batch AHPVA056AA) and the third dose on the 23rd March 2010 (batch AHPVA070AA, expiry 10/2011). The nurse reported that ten days after the third dose of CERVARIX had been administered the patient became poorly. The patient was admitted into ICU where she stayed for six weeks and was diagnosed with Guillian Barre Syndrome. The nurse reported that the patient is now out of ICU but still in hospital with pain and paralysis. The patient had no history of having any immunisations or vaccinations. There was no further information available at the time of reporting


VAERS ID: 390495 (history)  
Form: Version 1.0  
Age: 15.0  
Sex: Female  
Location: Foreign  
Vaccinated:2008-12-09
Onset:2008-12-20
   Days after vaccination:11
Submitted: 2010-06-11
   Days after onset:537
Entered: 2010-06-11
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS AHPVA023DP / UNK UN / IM

Administered by: Other       Purchased by: Other
Symptoms: Joint contracture, Oropharyngeal pain, Pain in extremity, Pyrexia
SMQs:, Neuroleptic malignant syndrome (broad), Anticholinergic syndrome (broad), Oropharyngeal conditions (excl neoplasms, infections and allergies) (narrow), Arthritis (broad), Tendinopathies and ligament disorders (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, 0 days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC Split Type: B0659637A

Write-up: This case was reported by a regulatory authority (#117897) and described the occurrence of pharyngodynia in a 15-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). On 9 December 2008, the subject received 1st dose of CERVARIX (intramuscular, unknown injection site). On 20 December 2008, 11 days after vaccination with CERVARIX, the subject experienced pharyngodynia with arm pain, contracture of fingers and fever. The subject was hospitalised. The subject was treated with ZIMOX and TACHIPIRINA. At the time of reporting the events were improved. The regulatory authority reported that the events were possibly related to vaccination with CERVARIX.


VAERS ID: 390608 (history)  
Form: Version 1.0  
Age: 16.0  
Sex: Female  
Location: Foreign  
Vaccinated:2009-11-25
Onset:2009-12-09
   Days after vaccination:14
Submitted: 2010-06-14
   Days after onset:186
Entered: 2010-06-14
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS AHPVA042AI / 3 UN / IM

Administered by: Other       Purchased by: Other
Symptoms: Alanine aminotransferase normal, Aspartate aminotransferase normal, Blood creatinine normal, Blood glucose increased, Blood potassium increased, Blood urea increased, Gamma-glutamyltransferase normal, Haematocrit normal, Haemoglobin normal, Hypoaesthesia, International normalised ratio normal, Mean cell haemoglobin, Mean cell volume normal, Muscle spasms, Pain in extremity, Paraesthesia, Platelet count normal, Prothrombin level increased, Red blood cell count normal, White blood cell count decreased
SMQs:, Acute renal failure (broad), Haematopoietic leukopenia (narrow), Peripheral neuropathy (broad), Hyperglycaemia/new onset diabetes mellitus (narrow), Systemic lupus erythematosus (broad), Retroperitoneal fibrosis (broad), Dystonia (broad), Guillain-Barre syndrome (broad), Chronic kidney disease (broad), Tumour lysis syndrome (narrow), Tendinopathies and ligament disorders (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Sexual dysfunction (broad)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, 0 days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: Alanine aminotransferase, 09Dec2009, 11IU; Aspartate aminotransferase, 09Dec2009, 26IU; Blood glucose, 09Dec2009, 114IU; Creatinine, 09Dec2009, 0.77IU; Gamma-glutamyltransferase, 09Dec2009, 18IU; Hematocrit, 09Dec2009, 40.5IU; Hemoglobin, 09Dec2009, 13.3IU; International normalized ratio, 09Dec2009, 1.08IU; Mean Corpuscular hemoglobin, 09Dec2009, 27IU; Mean corpuscular volume, 09Dec2009, 82.3IU; Platelet count, 09Dec2009, 243IU; Potassium, 09Dec2009, 5.15mmol; Prothrombin, 09Dec2009, 94IU; Red blood cell count, 09Dec2009, 4.92IU; Urea, 09Dec2009, 23IU; White blood cell count, 09Dec2009, 4.42IU
CDC Split Type: B0659212A

Write-up: This case was reported by a regulatory authority (# 117895) and described the occurrence of paresthesia in a 16-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). On 25 November 2009, the subject received 3rd dose of CERVARIX (intramuscular, unknown injection site). On 9 December 2009, 14 days after vaccination with CERVARIX, the subject experienced paresthesia, hypoesthesia, cramp and pain at right arm. The subject was hospitalised. Lab tests were performed and showed the following: Potassium: 5.15 mmol; White blood cells: 4.42; Red blood cells: 4.92; Hemoglobin: 13.3; Hematocrit: 40.5; Mean Corpuscolar Volume: 82.3; Mean Corpuscolar Hemoglobin: 27; Mean Corpuscolar Hemoglobin Concentration: 2.8; Red blood distribution width: 12.8; Platelets: 243; Glucose: 114; Urea: 23; Creatinine: 0.77; Alanineaminotransferase: 11; Aspartateaminotransferase: 26; Gammaglutamil transferase: 18; INR: 1.08; Prothrombin: 94. At the time of reporting the events were improved. The regulatory authority reported that the events were possibly related to vaccination with CERVARIX.


VAERS ID: 390721 (history)  
Form: Version 1.0  
Age: 14.0  
Sex: Female  
Location: Foreign  
Vaccinated:2010-06-09
Onset:2010-06-09
   Days after vaccination:0
Submitted: 2010-06-15
   Days after onset:6
Entered: 2010-06-15
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS AHPVA060DC / UNK LL / IM

Administered by: Other       Purchased by: Other
Symptoms: Convulsion, Loss of consciousness, Syncope
SMQs:, Torsade de pointes/QT prolongation (broad), Hyperglycaemia/new onset diabetes mellitus (broad), Neuroleptic malignant syndrome (broad), Systemic lupus erythematosus (broad), Anticholinergic syndrome (broad), Arrhythmia related investigations, signs and symptoms (broad), Convulsions (narrow), Noninfectious encephalitis (broad), Noninfectious encephalopathy/delirium (broad), Noninfectious meningitis (broad), Cardiomyopathy (broad), Hypotonic-hyporesponsive episode (broad), Generalised convulsive seizures following immunisation (narrow), Hypoglycaemia (broad)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, 2 days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC Split Type: B0660679A

Write-up: This case was reported by a physician and described the occurrence of convulsions generalized in a 14-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). The subject was healthy and sportive, with no history of allergy or disease. On 9 June 2010, the subject received 1st dose of CERVARIX (intramuscular, unknown injection site). On 9 June 2010, 5 minutes after vaccination with CERVARIX, the subject experienced convulsions generalized similar to epileptic paroxysm during 5 seconds, followed by syncope with loss of consciousness during 1 minute. The events spontaneously resolved. The subject was brought to hospital by her father and was hospitalised for observation during 2 days. On 9 June 2010, the events were resolved.


VAERS ID: 390785 (history)  
Form: Version 1.0  
Age: 25.0  
Sex: Female  
Location: Foreign  
Vaccinated:2010-03-26
Onset:2010-03-26
   Days after vaccination:0
Submitted: 2010-06-16
   Days after onset:82
Entered: 2010-06-16
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS AHPVA020CC / 3 UN / UN

Administered by: Other       Purchased by: Other
Symptoms: Antineutrophil cytoplasmic antibody negative, Antinuclear antibody negative, Borrelia test negative, CSF immunoglobulin increased, CSF oligoclonal band present, Computerised tomogram head, Computerised tomogram normal, Hypoaesthesia, Lactose intolerance, Lumbar puncture abnormal, Nerve stimulation test normal, Nuclear magnetic resonance imaging abnormal, Nuclear magnetic resonance imaging normal, Paraesthesia, Pleocytosis, Polymerase chain reaction, Post lumbar puncture syndrome, Red blood cell sedimentation rate normal, Sensory disturbance, Somatosensory evoked potentials, Visual evoked potentials normal
SMQs:, Peripheral neuropathy (narrow), Guillain-Barre syndrome (broad), Noninfectious encephalitis (broad), Noninfectious meningitis (broad), Immune-mediated/autoimmune disorders (broad), Sexual dysfunction (broad)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, 7 days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Birth twin; Cervical vertebra injury; discordant twin; family history of multiple sclerosis
Preexisting Conditions: Triplet pregnancy, delivered
Allergies:
Diagnostic Lab Data: Examination: Computed tomogram of cranium on 27 April 2010: normal; Cranial magnetic resonance tomogram on 28 April 2010: no hint for inflammatory lesions: Magnetic resonance tomogram of cervical spine on 30 April 2010: mildly reduced fluid signal of intervertebral disk cervical vertebral body 4 to like degenerative changes, most likely an older inflammatory lesion, liquor signal uneventful; Lumbar puncture on 28 April 2010: pleocytosis of 9 cells, local immunoglobuline synthesis IgG 67%, positive for oligoclonal bands; Laboratory examination of serum: negative for Borrelia; Electrophysiological examination 28 April 2010: normal motor evoked potential, normal visual evoked potential, normal somatosensory evoked potential; Erythrocyte sedimentation rate: normal, no hint for autoimmune vasculitis; Nephrology on 28 April 2010: ANCA immunofluorescence negative , ANA immunofluorescence increased with a value of 1:160, ANA screen normal with a value of 0.3 ration/negative.
CDC Split Type: D0067855A

Write-up: This case was reported by a neurologist and described the occurrence of numb sensation in a 25-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). According to the consumer''s report, she developed approximately 2 weeks after 3rd vaccination with CERVARIX numb sensation and sensory disturbances from slightly to moderate at right leg. On 27 April 2010, these sensations spread out in whole right half of body inclusive of right half of face and forehead. Therefore, the subject was hospitalised at neurological unit. Symptoms resolved without any treatment. According to the physician''s report, the subject was triplet (triplet pregnancy and delivered) and had one monovular (birth twin) and one biovular sister (discordant twin). The triovular triplet (as reporter) developed multiple sclerosis. Medical history did not include paresthesia, hypesthesia, visual disturbance and paresis. Magnetic resonance tomogram of cervical spine showed older cervical vertebra injury. On 26 March 2010, 12 November 2009 and 10 September 2009 the subject received 3rd dose, 2nd dose and 1st dose of CERVARIX (unknown route and application site) from her gynaecologist. On 27 April 2010, the subject was hospitalised in emergency admission due to numb sensation of right leg, which persisted already 1 week. In further course, symptoms spread out to hemihypesthesia at upper extremities and right side of face. She developed paresthesia including tingling in right leg. She did not develop headache. After several examinations, no hint for autoimmune vasculitis was found. Hemihypesthesia improved in further course. The physician diagnosed possible chronic central nervous system inflammation, hemihypesthesia of right side of the body, pleocytosis in cerebrospinal fluid, oligoclonal bands present in cerebrospinal fluid, post lumbar puncture syndrome and lactose intolerance. Polymerase chain reaction (PCR) to search for Varicella zoster and Herpes simplex was performed, but results were outstanding. In summary, the physician suspected inflammatory genesis of hemihypesthesia most likely, which was provoked by vaccination with CERVARIX. The physician did not surely base the diagnosis of chronic inflammatory central nervous system process due to normal results of magnetic resonance tomogram of cranium and cervical spine. When the subject was discharged from hospital on 03 May 2010, focal neurological deficit was resolved. The subject was hospitalised for 7 days and the physician considered the events were clinically significant (or requiring intervention). At the time of reporting the outcome of the other events was unspecified. Follow-up information has been requested.


Result pages: prev   5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23   next

New Search

Link To This Search Result:

https://www.medalerts.org/vaersdb/findfield.php?EVENTS=ON&PAGENO=14&VAX=HPV2&SERIOUS=ON


Copyright © 2022 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166